Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

The effects of TPA023, a GABAAα2,3 subtype-selective partial agonist, on essential tremor in comparison to alcohol.

de Haas SL, Zoethout RW, Van Dyck K, De Smet M, Rosen LB, Murphy MG, Gottesdiener KM, Schoemaker RC, Cohen AF, van Gerven JM.

J Psychopharmacol. 2012 Feb;26(2):282-91. doi: 10.1177/0269881111415731. Epub 2011 Sep 2.

PMID:
21890585
2.

The effects of a novel histamine-3 receptor inverse agonist on essential tremor in comparison to stable levels of alcohol.

Zoethout RW, Iannone R, Bloem BR, Palcza J, Murphy G, Chodakewitz J, Buntinx A, Gottesdiener K, Marsilio S, Rosen L, van Dyck K, Louis ED, Cohen AF, Schoemaker RC, Tokita S, Sato N, Koblan KS, Hargreaves RH, Renger J, van Gerven JM.

J Psychopharmacol. 2012 Feb;26(2):292-302. doi: 10.1177/0269881111398685. Epub 2011 Feb 18.

PMID:
21335358
3.

Pharmacokinetic-pharmacodynamic relationships of central nervous system effects of scopolamine in healthy subjects.

Liem-Moolenaar M, de Boer P, Timmers M, Schoemaker RC, van Hasselt JG, Schmidt S, van Gerven JM.

Br J Clin Pharmacol. 2011 Jun;71(6):886-98. doi: 10.1111/j.1365-2125.2011.03936.x.

4.

Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant.

Hoever P, de Haas S, Winkler J, Schoemaker RC, Chiossi E, van Gerven J, Dingemanse J.

Clin Pharmacol Ther. 2010 May;87(5):593-600. doi: 10.1038/clpt.2010.19. Epub 2010 Apr 7.

PMID:
20376002
5.

Central nervous system effects of alcohol at a pseudo-steady-state concentration using alcohol clamping in healthy volunteers.

Zoethout RW, Schoemaker RC, Zuurman L, van Pelt H, Dahan A, Cohen AF, van Gerven JM.

Br J Clin Pharmacol. 2009 Oct;68(4):524-34. doi: 10.1111/j.1365-2125.2009.03488.x.

6.

Pharmacokinetics, pharmacodynamics and the pharmacokinetic/ pharmacodynamic relationship of zolpidem in healthy subjects.

de Haas SL, Schoemaker RC, van Gerven JM, Hoever P, Cohen AF, Dingemanse J.

J Psychopharmacol. 2010 Nov;24(11):1619-29. doi: 10.1177/0269881109106898. Epub 2009 Jul 31.

PMID:
19648220
7.

Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study.

Wirtz PW, Verschuuren JJ, van Dijk JG, de Kam ML, Schoemaker RC, van Hasselt JG, Titulaer MJ, Tjaden UR, den Hartigh J, van Gerven JM.

Clin Pharmacol Ther. 2009 Jul;86(1):44-8. doi: 10.1038/clpt.2009.35. Epub 2009 Apr 8.

PMID:
19357643
8.

Clinically important interaction between tedisamil and verapamil.

van Haarst AD, Dijkmans AC, Weimann HJ, Kemme MJ, Bosch JJ, Schoemaker RC, Cohen AF, Burggraaf J.

J Clin Pharmacol. 2009 May;49(5):560-7. doi: 10.1177/0091270009332812. Epub 2009 Mar 19.

PMID:
19299533
9.

Acute psychomotor effects of MDMA and ethanol (co-) administration over time in healthy volunteers.

Dumont GJ, Schoemaker RC, Touw DJ, Sweep FC, Buitelaar JK, van Gerven JM, Verkes RJ.

J Psychopharmacol. 2010 Feb;24(2):155-64. doi: 10.1177/0269881108099214. Epub 2009 Jan 22.

PMID:
19164498
10.

Ethanol co-administration moderates 3,4-methylenedioxymethamphetamine effects on human physiology.

Dumont GJ, Kramers C, Sweep FC, Willemsen JJ, Touw DJ, Schoemaker RC, van Gerven JM, Buitelaar JK, Verkes RJ.

J Psychopharmacol. 2010 Feb;24(2):165-74. doi: 10.1177/0269881108100020. Epub 2008 Dec 12.

PMID:
19074534
11.

A comparative study of two methods for attaining constant alcohol levels.

Zoethout RW, van Gerven JM, Dumont GJ, Paltansing S, van Burgel ND, van der Linden M, Dahan A, Cohen AF, Schoemaker RC.

Br J Clin Pharmacol. 2008 Nov;66(5):674-81. doi: 10.1111/j.1365-2125.2008.03268.x.

12.

Inhibition of THC-induced effects on the central nervous system and heart rate by a novel CB1 receptor antagonist AVE1625.

Zuurman L, Roy C, Schoemaker RC, Amatsaleh A, Guimaeres L, Pinquier JL, Cohen AF, van Gerven JM.

J Psychopharmacol. 2010 Mar;24(3):363-71. doi: 10.1177/0269881108096509. Epub 2008 Sep 18.

PMID:
18801827
13.

Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol.

Liem-Moolenaar M, Gray FA, de Visser SJ, Franson KL, Schoemaker RC, Schmitt JA, Cohen AF, van Gerven JM.

J Psychopharmacol. 2010 Jan;24(1):73-82. doi: 10.1177/0269881108094524. Epub 2008 Aug 28.

PMID:
18755817
14.

Modelling of the concentration--effect relationship of THC on central nervous system parameters and heart rate -- insight into its mechanisms of action and a tool for clinical research and development of cannabinoids.

Strougo A, Zuurman L, Roy C, Pinquier JL, van Gerven JM, Cohen AF, Schoemaker RC.

J Psychopharmacol. 2008 Sep;22(7):717-26. doi: 10.1177/0269881108089870. Epub 2008 Jun 26.

PMID:
18583433
15.

Effect of intrapulmonary tetrahydrocannabinol administration in humans.

Zuurman L, Roy C, Schoemaker RC, Hazekamp A, den Hartigh J, Bender JC, Verpoorte R, Pinquier JL, Cohen AF, van Gerven JM.

J Psychopharmacol. 2008 Sep;22(7):707-16. doi: 10.1177/0269881108089581. Epub 2008 May 30.

PMID:
18515447
16.

Ciclosporin kinetics in children after stem cell transplantation.

Willemze AJ, Cremers SC, Schoemaker RC, Lankester AC, den Hartigh J, Burggraaf J, Vossen JM.

Br J Clin Pharmacol. 2008 Oct;66(4):539-45. doi: 10.1111/j.1365-2125.2008.03217.x. Epub 2008 Apr 30.

17.

Autonomic nervous system function in chronic exogenous subclinical thyrotoxicosis and the effect of restoring euthyroidism.

Eustatia-Rutten CF, Corssmit EP, Heemstra KA, Smit JW, Schoemaker RC, Romijn JA, Burggraaf J.

J Clin Endocrinol Metab. 2008 Jul;93(7):2835-41. doi: 10.1210/jc.2008-0080. Epub 2008 Apr 8.

PMID:
18397977
18.

Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy.

Broeyer FJ, Osanto S, Ritsema van Eck HJ, van Steijn AQ, Ballieux BE, Schoemaker RC, Cohen AF, Burggraaf J.

J Cancer Res Clin Oncol. 2008 Sep;134(9):961-8. doi: 10.1007/s00432-008-0372-8. Epub 2008 Mar 15.

19.

MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers.

Boot JD, De Haas SL, Van Gerven JM, De Smet M, Leathem T, Wagner J, Denker A, Miller D, Van Doorn MB, Schoemaker RC, Cohen AF, Diamant Z.

Pulm Pharmacol Ther. 2008;21(3):573-7. doi: 10.1016/j.pupt.2008.01.009. Epub 2008 Feb 3.

PMID:
18321743
20.

Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa.

Smarius LJ, Jacobs GE, Hoeberechts-Lefrandt DH, de Kam ML, van der Post JP, de Rijk R, van Pelt J, Schoemaker RC, Zitman FG, van Gerven JM, Gijsman HJ.

J Psychopharmacol. 2008 Jun;22(4):426-33. doi: 10.1177/0269881107082025. Epub 2008 Feb 28.

PMID:
18308795
21.

Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA(A) alpha2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers.

de Haas SL, de Visser SJ, van der Post JP, Schoemaker RC, van Dyck K, Murphy MG, de Smet M, Vessey LK, Ramakrishnan R, Xue L, Cohen AF, van Gerven JM.

J Psychopharmacol. 2008 Jan;22(1):24-32. doi: 10.1177/0269881107082108.

PMID:
18187530
22.

Effect of garlic powder on C-reactive protein and plasma lipids in overweight and smoking subjects.

van Doorn MB, Espirito Santo SM, Meijer P, Kamerling IM, Schoemaker RC, Dirsch V, Vollmar A, Haffner T, Gebhardt R, Cohen AF, Princen HM, Burggraaf J.

Am J Clin Nutr. 2006 Dec;84(6):1324-9.

PMID:
17158412
23.

Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers.

de Haas SL, de Visser SJ, van der Post JP, de Smet M, Schoemaker RC, Rijnbeek B, Cohen AF, Vega JM, Agrawal NG, Goel TV, Simpson RC, Pearson LK, Li S, Hesney M, Murphy MG, van Gerven JM.

J Psychopharmacol. 2007 Jun;21(4):374-83. Epub 2006 Nov 8.

PMID:
17092968
24.

Pharmacokinetics and systemic endocrine effects of the phyto-oestrogen 8-prenylnaringenin after single oral doses to postmenopausal women.

Rad M, Hümpel M, Schaefer O, Schoemaker RC, Schleuning WD, Cohen AF, Burggraaf J.

Br J Clin Pharmacol. 2006 Sep;62(3):288-96.

25.
26.

A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema.

van Doorn MB, Burggraaf J, van Dam T, Eerenberg A, Levi M, Hack CE, Schoemaker RC, Cohen AF, Nuijens J.

J Allergy Clin Immunol. 2005 Oct;116(4):876-83. Epub 2005 Aug 8.

PMID:
16210064
27.

AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients.

Scholten EM, Cremers SC, Schoemaker RC, Rowshani AT, van Kan EJ, den Hartigh J, Paul LC, de Fijter JW.

Kidney Int. 2005 Jun;67(6):2440-7.

28.

Reversal of the late asthmatic response increases exhaled nitric oxide.

Boot JD, Tarasevych S, Sterk PJ, Schoemaker RC, Wang L, Amin D, Cohen AF, Diamant Z.

Respir Med. 2005 Dec;99(12):1591-4. No abstract available.

29.

Relationship between airway responsiveness to neurokinin A and methacholine in asthma.

Cohen J, Burggraaf J, Schoemaker RC, Sterk PJ, Cohen AF, Diamant Z.

Pulm Pharmacol Ther. 2005;18(3):171-6. Epub 2005 Jan 22.

PMID:
15707850
30.

Factors predicting the blood glucose lowering effect of a 30-day very low calorie diet in obese Type 2 diabetic patients.

Jazet IM, Pijl H, Frölich M, Schoemaker RC, Meinders AE.

Diabet Med. 2005 Jan;22(1):52-5.

PMID:
15606691
31.

Pharmacokinetics of oral fumarates in healthy subjects.

Litjens NH, Burggraaf J, van Strijen E, van Gulpen C, Mattie H, Schoemaker RC, van Dissel JT, Thio HB, Nibbering PH.

Br J Clin Pharmacol. 2004 Oct;58(4):429-32.

32.

Pharmacokinetic/pharmacodynamic assessment of tolerance to central nervous system effects of a 3 mg sustained release tablet of rilmenidine in hypertensive patients.

van der Post JP, de Visser SJ, Schoemaker RC, Cohen AF, van Gerven JM.

J Psychopharmacol. 2004 Jun;18(2):221-7.

PMID:
15260911
33.

Pharmacokinetics of rectal tramadol in postoperative paediatric patients.

Zwaveling J, Bubbers S, van Meurs AH, Schoemaker RC, van Heel IR, Vermeij P, Burggraaf J.

Br J Anaesth. 2004 Aug;93(2):224-7. Epub 2004 May 28.

34.

Effects of a nonpeptide motilin receptor antagonist on proximal gastric motor function.

Kamerling IM, van Haarst AD, Burggraaf J, Schoemaker RC, de Kam ML, Heinzerling H, Cohen AF, Masclee AA.

Br J Clin Pharmacol. 2004 Apr;57(4):393-401.

35.

The psychomotor effects of carbamazepine in epileptic patients and healthy volunteers.

Pieters MS, van Steveninck AF, Schoemaker RC, Kroon JM, van Gerven JM, Cohen AF.

J Psychopharmacol. 2003 Sep;17(3):269-72.

PMID:
14513917
36.

Central nervous system effects of moxonidine experimental sustained release formulation in patients with mild to moderate essential hypertension.

Kemme MJ, vd Post JP, Schoemaker RC, Straub M, Cohen AF, van Gerven JM.

Br J Clin Pharmacol. 2003 Jun;55(6):518-25.

37.

Endothelial binding of recombinant tissue plasminogen activator: quantification in vivo using a recirculatory model.

Kemme MJ, Schoemaker RC, Burggraaf J, van der Linden M, Noordzij M, Moerland M, Kluft C, Cohen AF.

J Pharmacokinet Pharmacodyn. 2003 Feb;30(1):3-22.

PMID:
12800805
38.

A compartmental pharmacokinetic model of cyclosporin and its predictive performance after Bayesian estimation in kidney and simultaneous pancreas-kidney transplant recipients.

Cremers SC, Scholten EM, Schoemaker RC, Lentjes EG, Vermeij P, Paul LC, den Hartigh J, de Fijter JW.

Nephrol Dial Transplant. 2003 Jun;18(6):1201-8.

PMID:
12748356
39.

Local tissue factor pathway inhibitor release in the human forearm.

Kemme MJ, Burggraaf J, Schoemaker RC, Cohen AF, Kluft C, Chia S, Webb DJ, Newby DE.

Thromb Haemost. 2003 Mar;89(3):438-45.

PMID:
12624625
40.

Motilin effects on the proximal stomach in patients with functional dyspepsia and healthy volunteers.

Kamerling IM, Van Haarst AD, Burggraaf J, Schoemaker RC, Biemond I, Heinzerling H, Jones R, Cohen AF, Masclee AA.

Am J Physiol Gastrointest Liver Physiol. 2003 May;284(5):G776-81. Epub 2003 Jan 2.

41.

Quantification of heparin-induced TFPI release: a maximum release at low heparin dose.

Kemme MJ, Burggraaf J, Schoemaker RC, Kluft C, Cohen AF.

Br J Clin Pharmacol. 2002 Dec;54(6):627-34.

42.

Saccadic peak velocity and EEG as end-points for a serotonergic challenge test.

Gijsman HJ, van Gerven JM, Verkes RJ, Schoemaker RC, Pieters MS, Pennings EJ, Hessing TJ, Cohen AF.

Hum Psychopharmacol. 2002 Mar;17(2):83-9.

PMID:
12404696
43.

Estimation of plasma serotonin using isopycnic centrifugation.

Gijsman HJ, Verkes RJ, Schouten-Verhagen JC, Schoemaker RC, Van Gerven JM, De Rijk RH, Van Kempen GM.

Hum Psychopharmacol. 2000 Aug;15(6):417-421.

PMID:
12404303
44.

Concentration-effect relationships of two rilmenidine single-dose infusion rates in hypertensive patients.

de Visser SJ, van der Post JP, Nanhekhan L, Schoemaker RC, Cohen AF, van Gerven JM.

Clin Pharmacol Ther. 2002 Oct;72(4):419-28.

PMID:
12386644
45.

Development of an optimal furosemide infusion strategy in infants with modeling and simulation.

Schoemaker RC, van dDer Vorst MM, van Heel IR, Cohen AF, Burggraaf J; Pediatric Pharmacology Network.

Clin Pharmacol Ther. 2002 Oct;72(4):383-90.

PMID:
12386640
46.

Absence of interaction of fondaparinux sodium with aspirin and piroxicam in healthy male volunteers.

Ollier C, Faaij RA, Santoni A, Duvauchelle T, van Haard PM, Schoemaker RC, Cohen AF, de Greef R, Burggraaf J.

Clin Pharmacokinet. 2002;41 Suppl 2:31-7.

PMID:
12383043
47.

The synthetic pentasaccharide fondaparinux sodium does not interact with oral warfarin.

Faaij RA, Burggraaf J, Schoemaker RC, de Greef R, Cohen AF.

Clin Pharmacokinet. 2002;41 Suppl 2:27-9. No abstract available.

PMID:
12383042
48.

Modeling the influence of growth hormone on lipolysis.

Schoemaker RC, Buijs MM, Pijl H, Burggraaf J, Cohen AF.

J Pharmacokinet Pharmacodyn. 2002 Apr;29(2):157-70.

PMID:
12361241
49.

Intraocular penetration and systemic absorption after topical application of dexamethasone disodium phosphate.

Weijtens O, Schoemaker RC, Romijn FP, Cohen AF, Lentjes EG, van Meurs JC.

Ophthalmology. 2002 Oct;109(10):1887-91.

PMID:
12359610
50.

Absence of an interaction between the synthetic pentasaccharide fondaparinux and oral warfarin.

Faaij RA, Burggraaf J, Schoemaker RC, Van Amsterdam RG, Cohen AF.

Br J Clin Pharmacol. 2002 Sep;54(3):304-8.

Supplemental Content

Loading ...
Support Center